TG crosses the finish line in MS, turning U2 component into standalone drug for biotech's second approval
TG Therapeutics finally got past the FDA and got a new MS drug approved that the company plans to commercialize against giants like Roche’s Ocrevus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
